| Literature DB >> 32872747 |
You-Jung Ha1,2, Hyo Jin Kim3, Eugene Lee4, Ji Hye Park5, Young Soo Park5, Yun Jong Lee1,2, Yusuhn Kang4, Hyuk Yoon5.
Abstract
BACKGROUND/AIMS: Sacroiliitis is a frequent extraintestinal manifestation of inflammatory bowel diseases (IBDs). This study aimed to assess the prevalence of sacroiliitis using a validated screening tool based on abdominopelvic computed tomography (APCT) in Korean patients with Crohn's disease (CD) and examine potential associations between clinical characteristics and sacroiliitis.Entities:
Keywords: Crohn disease; Sacroiliac joint; Sacroiliitis; Tomography, spiral computed
Mesh:
Year: 2021 PMID: 32872747 PMCID: PMC8273833 DOI: 10.3904/kjim.2020.199
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Figure 1Participant selection for this study on sacroiliitis in patients with Crohn’s disease (n = 114). CT, computed tomography; SNUBH, Seoul National University Bundang Hospital; IBD, inflammatory bowel diseases; DISH, diffuse idiopathic skeletal hyperostosis.
Baseline demographics and prevalence of sacroiliitis and its features in Korean patients with Crohn’s disease (n = 105) and control group (n = 105)
| Variable | Crohn’s disease (n = 105) | Control (n = 105) | |
|---|---|---|---|
| Age, yr | 29.3 ± 10.6 | 29.3 ± 10.6 | NA |
| Male sex | 81 (77.1) | 81 (77.1) | NA |
| Presence of sacroiliitis | 14 (13.3) | 5 (4.8) | 0.030 |
| Ankylosis | 0 | 0 | NA |
| Total erosion score | 0.89 ± 0.13 | 0.55 ± 0.08 | 0.032 |
| Total erosion score ≥ 3 | 14 (13.3) | 5 (4.8) | 0.030 |
| Presence of any site sclerosis | 2 (1.9) | 2 (1.9) | 1.000 |
| Bilateral | 14/14 (100) | 4/5 (80) | 0.086 |
Values are presented as mean ± standard deviation or number (%).
NA, not applicable.
Significant at 5% level of significance.
Figure 2Axial view of abdominopelvic computed tomography scan showed an erosion on the left iliac side of the sacroiliac joint (yellow arrow).
Figure 3Total erosion score distributions in patients with Crohn’s disease (n = 105) and controls (n = 105).
Interreader reliability for the computed tomography examination of the sacroiliac joints in all subjects (n = 210)
| Variable | Interreader reliability |
|---|---|
| Ankylosis (κ) | 0.995 |
| Presence of erosion (κ) | 0.938 |
| Total erosion score (ICC) | 0.891 |
| Sclerosis (κ) | 0.981 |
| Presence of sacroiliitis (κ) | 0.933 |
ICC, intraclass correlation coefficient.
Comparison of the demographics and clinical characteristics according to the presence of sacroiliitis
| Variable | Total (n = 105) | Sacroiliitis (n = 14) | No sacroiliitis (n = 91) | |
|---|---|---|---|---|
| Age at diagnosis | 26.5 ± 10.4 | 26.1 ± 13.5 | 26.5 ± 9.9 | 0.892 |
| Age, yr | 0.396 | |||
| < 17 | 8 (7.6) | 2 (14.3) | 6 (6.6) | |
| ≥ 17 and < 40 | 88 (85.7) | 10 (71.4) | 78 (85.7) | |
| ≥ 40 | 9 (8.6) | 2 (14.3) | 7 (7.7) | |
| Male sex | 81 (77.1) | 10 (71.4) | 71 (78.0) | 0.584 |
| Family history of IBD | 6 (5.7) | 2 (14.3) | 4 (4.4) | 0.138 |
| Smoking | 0.665 | |||
| Never-smoker | 66 (62.9) | 10 (71.4) | 56 (61.5) | |
| Ex-smoker | 14 (13.3) | 2 (14.3) | 12 (13.2) | |
| Current-smoker | 25 (23.8) | 2 (14.3) | 23 (25.3) | |
| Disease duration, yr | 2.81 ± 4.25 | 1.73 ± 2.60 | 2.98 ± 4.43 | 0.308 |
| Location | 0.373 | |||
| L1 | 27 (25.7) | 2 (14.3) | 25 (27.5) | |
| L2 | 3 (2.9) | 1 (7.1) | 2 (2.2) | |
| L3 | 75 (71.4) | 11 (78.6) | 64 (70.3) | |
| L4 | 12 (11.4) | 0 | 12 (13.2) | 0.149 |
| Behavior | 0.180 | |||
| B1 | 52 (49.5) | 9 (64.3) | 43 (47.3) | |
| B2 | 15 (14.3) | 3 (21.4) | 12 (13.2) | |
| B3 | 38 (36.2) | 2 (14.3) | 36 (39.6) | |
| Perianal disease | 43 (41.0) | 4 (28.6) | 39 (42.9) | 0.312 |
| CDAI (available no.) | 172.2 ± 25.7 (29) | 136.5 ± 124.5 (2) | 174.8 ± 26.7 (27) | 0.713 |
| Extraintestinal manifestation | ||||
| Arthritis/arthralgia | 12 (11.4) | 2 (14.3) | 10 (11.0) | 0.718 |
| Eye involvement | 4 (3.8) | 1 (7.1) | 3 (3.3) | 0.484 |
| Skin involvement | 14 (13.3) | 1 (7.1) | 13 (14.3) | 0.464 |
| Operation history | ||||
| Abdominal | 16 (15.2) | 0 | 16 (17.6) | 0.088 |
| Perianal | 37 (35.2) | 4 (28.6) | 33 (36.3) | 0.575 |
| Hospitalization history | 77 (73.3) | 10 (81.4) | 67 (73.6) | 0.575 |
| ER visit history | 60 (57.1) | 7 (50.0) | 53 (58.2) | 0.562 |
| Medications history | ||||
| Corticosteroids | 67 (63.8) | 9 (64.3) | 58 (63.7) | 0.968 |
| Immunomodulators | 62 (59.1) | 5 (35.7) | 57 (62.6) | 0.057 |
| Anti-TNFα | 27 (25.7) | 3 (21.4) | 24 (26.4) | 0.693 |
| Laboratory findings (observed no.) | ||||
| White blood cell count, /mm3 | 8,069 ± 359 (91) | 8,228 ± 879 (11) | 8,047 ± 392 (80) | 0.870 |
| Hemoglobin, mg/dL | 13.3 ± 0.2 (91) | 12.8 ± 0.8 (11) | 13.3 ± 0.2 (80) | 0.435 |
| ESR, mm/hr | 27.1 ± 3.8 (82) | 27.7 ± 12.6 (10) | 27.0 ± 4.0 (72) | 0.952 |
| C-reactive protein, mg/dL | 2.8 ± 0.5 (88) | 2.2 ± 0.9 (11) | 2.9 ± 0.6 (77) | 0.671 |
| Fecal calprotectin, mg/kg | 834.1 ± 109.8 (42) | 421.4 ± 264.1 (3) | 865.9 ± 115.5 (39) | 0.303 |
| ASCA IgG | 29.1 ± 2.1 (98) | 24.0 ± 4.4 (14) | 29.9 ± 2.3 (84) | 0.328 |
| Positive for ASCA IgG | 48 (49.0) | 6 (42.9) | 42 (50.0) | 0.621 |
| ASCA IgA | 17.8 ± 1.5 (73) | 23.9 ± 6.2 (11) | 16.7 ± 1.4 (62) | 0.093 |
| Positive for ASCA IgA | 17 (17.4) | 4 (28.6) | 13 (15.5) | 0.231 |
| Positive for ANCA IIF | 1/32 (3.0) | 0/5 (0) | 1/27 (3.6) | 0.184 |
Values are presented as mean ± standard deviation or number (%).
IBD, inflammatory bowel disease; CDAI, Crohn’s disease activity index; ER, emergency room; TNF, tumor necrosis factor; ESR, erythrocyte sedimentation rate; ASCA, anti-Saccharomyces cerevisiae antibody; ANCA, anti-neutrophilic cytoplasmic antibody; Ig, immunoglobulin; IIF, indirect immunofluorescence.